Fulgent Genetics Inc. reported its second quarter 2025 financial results, highlighting a 16% year-over-year increase in core revenue, reaching $81.7 million. The company has raised its full-year 2025 core revenue guidance to $320 million. Fulgent recorded a GAAP gross profit of $34.4 million, with a GAAP gross margin of 42.1%, while the non-GAAP gross profit stood at $36.2 million, or a non-GAAP gross margin of 44.2%. The company reported a GAAP loss of $19.0 million, or ($0.62) per share, which includes a one-time charge. On a non-GAAP basis, Fulgent posted an income of $2.1 million. Fulgent concluded the second quarter with $777.5 million in cash, cash equivalents, restricted cash, and investments in marketable securities. The company continues to focus on growing its Laboratory Services business and advancing clinical trials for its Therapeutic Development business.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.